제 2형 당뇨병 치료제의 개발 동향

키워드

참고문헌 (57)

1. Abbatecola, A. M, "New approaches to treating type 2 diabetes mellitus in the elderly: Role of incretin therapies", Drugs Aging, 25, pp.913~925 (2008)
2. Ahrén, B, "The islet enhancer vildagliptin: Mechanisms of improved glucose metabolism", Int. J. Clin.Pract, 62, pp.8~14 (2008)
3. Ahren, B, "The future of incretin-based therapy: Novel avenues-novel targets", Diabetes, Obes. Metab, 13, pp.158~166 (2011)
4. Ahren, B., "Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events", Best Pract. Res. Clin. Endoc. Metab, 23, pp.487~498 (2009)
5. Ahren, B, "GLP-1 for type 2 diabetes", Exp. Cell Res, 317, pp.1239~1245 (2011)
6. Atkins, R. C., "The epidemiology of chronic kidney disease", Kidney Int, 67, pp.S14~S18 (2005)
7. Bagust, A, "Deteriorating beta-cell function in type 2 diabetes: A long-term model", QJM, 96, pp.281~288 (2003)
8. ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes, "Clin. Ther", 2005, 1181~1195
9. Buse, J. B., "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)", J. Lancet, 374, pp.39~47 (2009)
10. Cariou, B, "Effects of the new dual PPARα", δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism, 2011, pp.34, 2008~2014
11. 최장현, "Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR gamma by Cdk5", NATURE, 466(7305), pp.451~1, NATURE PUBLISHING GROUP
12. 최장현, "Antidiabetic actions of a non-agonist PPAR gamma ligand blocking Cdk5-mediated phosphorylation", NATURE, 477(7365), pp.477~131, NATURE PUBLISHING GROUP
13. Congdon, N. G, "Important causes of visual impairment in the world today", JAMA, J. Am. Med. Assoc, 290, pp.2057~2060 (2003)
14. Drucker, D. J, "The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", J. Lancet, 368, pp.1696~1705 (2006)
15. Dunning, B, "Alpha cell function in health and disease: Influence of glucagon-like peptide-1", Diabetologia, 48, pp.1700~1713 (2005)
16. Flegal, K. M, "Prevalence and trends in obesity among US adults, 1999-2008", J. Am. Vet. Med. Assoc, 303, pp.235~241 (2008)
17. Gilbert, M. P, "Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus", Eur. J. Intern. Med, 20, pp.S309~S318 (2009)
18. Gomis, R, "Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study", Diabetes, Obes. Metab, 13, pp.653~661 (2011)
19. Gregg, E. W, "Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the US", Diabetes Care, 27, pp.2806~2812 (2004)
20. Home, P. D, "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial", J. Lancet, 373, pp.2125~2135 (2009)
21. 홍은경, "노인 당뇨병 환자의 약물 치료", 대한내과학회지, 80(6), pp.635~642 (2011), 대한내과학회
22. Hundal, R. S, "Mechanism by which metformin reduces glucose production in type 2 diabetes", Diabetes, 49, pp.2063~2069 (2000)
23. Kahn, S. E, "Rosiglitazone-associated fractures in type 2 diabetes", Diabetes Care, 31, pp.845~851 (2008)
24. Kecskemeti, V, "New trends in the development of oral antidiabetic drugs", Curr. Med. Chem, 9, pp.53~71 (2002)
25. 김재현, "인크레틴을 기초로 한 제2형 당뇨병의 복합약물요법", 대한의사협회지, 52(10), pp.1030~1036 (2009), 대한의사협회
26. 김신곤, "특집", 우리나라 당뇨병의 현황, 2008, pp.51(9), 791~798[DOI]
27. King, H, "Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections", Diabetes Care, 21, pp.1414~1431 (1998)
28. Knop, F. K, "Incretin-based therapy of type 2 diabetes mellitus", Curr. Protein Pept. Sci, 10, pp.46~55 (2009)
29. Knudsen, L., "Liraglutide: The therapeutic promise from animal models", Int. J. Clin. Pract, 64, pp.4~11 (2010)
30. Kokil, G. R, "Pharmacology and chemistry of diabetes mellitus and antidiabetic drugs: A critical review", Curr. Med. Chem, 17, pp.4405~4423 (2010)
31. Lebovitz, H, "Insulin secretagogues: Old and new", Diabetes Rev, 7, pp.139~153 (1999)
32. Lipscombe, L. L, "Trends in diabetes prevalence, incidence, and mortality in ontario, canada 1995-2005: A population-based study", J. Lancet, 369, pp.750~756 (2007)
33. Luo, J., "Time trends of obesity in preschool children in china from 1989 to 1997", Int. J. Obes, 26, pp.553~558 (1997)
34. Masana Marin, L, "Thiazolidindiones: Drugs for cardiovascular prevention", Med. Clin.(Barc), 118, pp.585~586 (2002)
35. Matthews, D., "Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study", Diabetes, Obes. Metab, 12, pp.780~789 (2010)
36. Nelson, P, "The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes", Diabetes Technol. Ther, 9, pp.317~326 (2007)
37. Nguyen, Q., "Evaluation and management of diabetes mellitus", Am Health and Drug Benefits, 1, pp.39~48 (2008)
38. Nissen, S. E, "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes", N. Engl. J. Med, 356, pp.2457~2471 (2007)
39. Norris, A. W, "A second chance for a PPARγ targeted therapy?", Circ. Res, 110, pp.8~11 (2012)
40. 오인환, "한국인의 질병부담", 대한의사협회지, 54(6), pp.646~652 (2011), 대한의사협회
41. Paton, C. M., "Biochemical and physiological function of stearoyl-CoA desaturase", Endocrino Metab, 297, pp.E28~E37 (2009)
42. Pavankuamr, V. V., "Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator", Eur. J. Drug Metab. Pharmacokinet, 32, pp.29~37 (2007)
43. Perfetti, R, "The role of GLP-1 in the life and death of pancreatic beta cells", Horm. Metab. Res, 36, pp.804~810 (2004)
44. Porte Jr, D, "Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications", Diabetes Metab. Res, 17, pp.181~188 (2001)
45. Punthakee, Z, "Design, history and results of the thiazolidinedione intervention with vitamin D evaluation(TIDE) randomised controlled trial", Diabetologia, 55, pp.36~45 (2012)
46. Schäfer, S, "A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion", Diabetologia, 52, pp.1075~1082 (2009)
47. Schäfer, S, "Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms", Diabetologia, 50, pp.2443~2450 (2007)
48. Shulman, G. I., "Cellular mechanisms of insulin resistance", J. Clin. Invest, 106, pp.171~176 (2000)
49. 필립쉐러, "Adipose tissue remodeling and obesity", Journal of Clinical Investigation, 121(6), pp.2094~2101, The American Society for Clinical Investigation
50. Tavani, A, "Diabetes mellitus as a contributor to the risk of acute myocardial infarction", J. Clin. Epidemiol, 55, pp.1082~1087 (2002)
51. Truscheit, E, "Microbial alpha-glucosidase inhibitors : Chemistry, biochemistry and therapeutic potential. Prog. Clin. Biochem. Med. 7 : 17-99", Prog. Clin. Biochem. Med, 7, pp.17~99 (1988)
52. Wild, S. H, "Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030", Diabetes Care, 27, pp.2569~2569 (2004)
53. Wilding, J. P. H, "Tesaglitazar, as add-on therapy to sulphonylurea, dosedependently improves glucose and lipid abnormalities in patients with type 2 diabetes", Diab. Vasc. Dis. Res, 4, pp.194~203 (2007)
54. Williams-Herman, D, "In patients with type 2 diabetes, sitagliptin effectively lowers A1c regardless of patient age, gender, or body mass index", Diabetes, 57, pp.A148~A148 (2008)
55. Zhao, G, "Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor", J. Med. Chem, 51, pp.380~383 (2008)
56. Zimmet, P, "Global and societal implications of the diabetes epidemic", Nature, 414, pp.782~787 (2001)
57. Zolotov, S, "Metabolic profiling in personalized medicine: Bridging the gap between knowledge and clinical practice in type 2 diabetes", Pers. Med, 8, pp.445~456 (2011)

관련 논문AI추천